Hepasan (Ornithine Aspartate)

Hepasan is indicated for conditions where liver function support and ammonia reduction are desired.

• Management of hepatic encephalopathy associated with chronic liver disease.
• Adjunct therapy for general liver dysfunction or mild hepatic impairment.
• Support of the urea cycle to facilitate ammonia detoxification.
• Use in patients with cirrhosis to help maintain hepatic metabolic balance.
• May be employed as part of a broader regimen for liver health maintenance.

Side effects of Hepasan are generally mild, but serious reactions can occur in rare cases.

Common

• Mild gastrointestinal discomfort or nausea.
• Diarrhea or loose stools.
• Transient headache.
• Mild abdominal bloating.
• Slight fatigue.

Serious

• Allergic reactions such as rash, itching, or swelling.
• Severe abdominal pain.
• Marked elevation of liver enzymes.
• Anaphylaxis (rare).

Before using Hepasan, consider the following safety information.

• Do not use if you have a known hypersensitivity to ornithine aspartate.
• Consult a healthcare professional before use during pregnancy or breastfeeding, as safety data are limited.
• Patients with severe liver failure should seek medical advice prior to use.
• Monitor ammonia levels regularly when used for hepatic encephalopathy.
• Keep the product out of reach of children and do not exceed the recommended dose.
• Inform your physician of any concurrent liver‑related medications or supplements.

Hepasan may interact with other substances that affect liver metabolism or ammonia levels.

Avoid

• Concurrent use with high‑dose ammonia‑lowering agents without medical supervision.
• Combining with known hepatotoxic drugs.

Use with caution

• Other hepatoprotective supplements (e.g., silymarin, milk thistle).
• Lactulose or rifaximin, which also target ammonia.
• Diuretics that may alter electrolyte balance.
• Alcohol consumption, which can exacerbate liver stress.
• Antibiotics that modify gut flora, potentially affecting ammonia production.